O. Okamoto

发表

L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2000, Biochemical and biophysical research communications.

A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814.

T. Ohe, M. Hata, A. Kanatani, 2001, Molecular pharmacology.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

J. Falgueyret, R. Rydzewski, M. Percival, 2001, Journal of medicinal chemistry.

Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist.

S. Okuda, S. Ozaki, Y. Ishii, 2009, Bioorganic & medicinal chemistry letters.

Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.

S. Ozaki, Y. Ishii, Yasushi Nagatomi, 2009, Bioorganic & medicinal chemistry letters.

Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.

S. Ozaki, S. Ito, H. Ohta, 2009, Bioorganic & medicinal chemistry letters.

A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2007, Molecular Pharmacology.

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.

D. Macneil, H. Iwaasa, L. V. D. van der Ploeg, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.

Y. Iwasawa, S. Okuda, S. Ozaki, 2006, Journal of medicinal chemistry.

An efficient enantioselective synthesis of the (-)-N-ethoxycarbonylmethyl Geissman-Waiss lactone: a practical synthetic route to (+)-retronecine

H. Niwa, Kiyoyuki Yamada, O. Okamoto, 1987 .

Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.

H. Iwaasa, M. Ando, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Efficient and practical asymmetric synthesis of 1-tert-butyl 3-methyl (3R,4R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine-1,3-dicarboxylate, a useful intermediate for the synthesis of nociceptin antagonists

Y. Iwasawa, J. Shibata, H. Kawamoto, 2009 .

Design, synthesis, and structure-activity relationship study of a novel class of ORL1 receptor antagonists based on N-biarylmethyl spiropiperidine.

S. Ozaki, H. Ohta, Masanori Asai, 2008, Bioorganic & medicinal chemistry letters.

1β-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems; 3. Synthesis and Antibacterial Activity of BO-2727 and Its Related Compounds

N. Ohtake, Y. Haga, O. Okamoto, 1997 .

Practical Syntheses of EnantiomericallyPure Key Intermediates of Opioid Receptor-like 1 (ORL1)Antagonists

H. Kigoshi, O. Okamoto, T. Yoshizumi, 2009 .

Total synthesis of optically active integerrimine, a twelve-membered dilactonic pyrrolizidine alkaloid of retronecine type

H. Niwa, H. Ishiwata, A. Kuroda, 1992 .

Total synthesis of optically active integerrimine, a twelve-membered dilactonic pyrrolizidine alkaloid of retronecine type. II. Enantioselective synthesis of (+)-retronecine

H. Niwa, Kiyoyuki Yamada, O. Okamoto, 1986 .

A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.

Hisashi Ohta, Hiroshi Kawamoto, Satoshi Ozaki, 2008, Journal of medicinal chemistry.

Diastereoselective synthesis of the key intermediate of the BO-2727 side chain

N. Ohtake, O. Okamoto, H. Jona, 1997 .

Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.

S. Ozaki, H. Ohta, Kensuke Kobayashi, 2009, Bioorganic & medicinal chemistry letters.

Total synthesis of optically active monocrotaline, a carcinogenic pyrrolizidine alkaloid possessing an eleven-membered retronecine dilactone

H. Niwa, Kiyoyuki Yamada, O. Okamoto, 1992 .

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

J. Falgueyret, R. Rydzewski, M. Percival, 2001, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists.

S. Ozaki, A. Satoh, H. Ohta, 2006, Bioorganic & medicinal chemistry letters.

An efficient asymmetric synthesis of the mercaptopyrrolidine side chain of an important β-methyl carbapenem antibiotic

J. Armstrong, J. Lynch, R. Volante, 1997 .

A Tin-Mediated One-Step Synthesis of (+)-Dicrotaline, an 11-Membered Dilactonic Pyrrolizidine Alkaloid

H. Niwa, H. Ishiwata, A. Kuroda, 1988 .

Total synthesis of optically active monocrotaline, a carcinogenic pyrrolizidine alkaloid having an 11-membered dilactone

H. Niwa, Kiyoyuki Yamada, O. Okamoto, 1988 .

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

H. Iwaasa, T. Ohe, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists.

D. Macneil, H. Iwaasa, A. Kanatani, 2009, Bioorganic & Medicinal Chemistry Letters.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.

H. Iwaasa, A. Kanatani, T. Fukami, 2009, Bioorganic & medicinal chemistry.

Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.

Hisashi Ohta, Hiroshi Kawamoto, Satoshi Ozaki, 2009, Journal of medicinal chemistry.

Synthesis and Antibacterial Activity of BO-2502 A and Its Related Compounds 1

Kato, N. Ohtake, Y. Haga, 2006 .

2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.

Hisashi Ohta, Hiroshi Kawamoto, Satoshi Ozaki, 2009, Bioorganic & medicinal chemistry letters.

Identification of novel benzimidazole series of potent and selective ORL1 antagonists.

Y. Iwasawa, S. Ozaki, Y. Ishii, 2008, Bioorganic & medicinal chemistry letters.

Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.

S. Ozaki, Y. Ishii, S. Ito, 2008, Bioorganic & medicinal chemistry letters.

Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human

Hisashi Ohta, Koen Van Laere, Osamu Okamoto, 2013, NeuroImage.

Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human

Sandra M. Sanabria-Bohórquez, G. Bormans, E. Hostetler, 2013, NeuroImage.

2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.

S. Ozaki, Y. Ishii, S. Ito, 2009, Bioorganic & medicinal chemistry letters.

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

H. Iwaasa, T. Ohe, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.